Lupin

₹2256.5 -31.8 | 1.4%

WEBSITE BSE:500257 NSE : LUPIN LTD. 06 Sep, 16:03

Market Cap ₹102927 Cr.

Stock P/E 45.4

P/B 4.8

Current Price ₹2256.5

Book Value ₹ 468.7

Face Value 2

52W High ₹2312

Dividend Yield 0.35%

52W Low ₹ 1091.8

Edit Ratio

Lupin Research see more...

Overview Inc. Year: 1983Industry: Pharmaceuticals & Drugs

Lupin Limited is an India-based pharmaceutical corporation. The Company develops and commercializes a variety of branded and general formulations, biotechnology merchandise, and active pharmaceutical substances (APIs) in over a hundred markets within the United States, India, South Africa, and throughout the Asia Pacific, Latin America, Europe, and the Middle East regions. It has presence inside the cardiovascular, diabetology, asthma, pediatrics, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug remedy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, amongst others. Its biosimilar merchandise include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter merchandise include Softovac, Lupizyme, Aptivate, Lupisafe, Be One and V-Bath, among others. The Company resources APIs for anti-retroviral, anti-malarial and tuberculosis (TB) remedy pills.

Lupin Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Lupin Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Lupin Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	8939	9752	11227	12753	10088	11356	11026	11056	11772	11259	14667
Other Income	415	181	187	88	131	291	475	129	221	210	126
Total Income	9355	9933	11414	12842	10219	11648	11501	11185	11993	11469	14793
Total Expenditure	6027	6379	7240	8267	8002	8504	9118	9012	11567	10295	11227
Operating Profit	3328	3554	4174	4575	2217	3144	2383	2173	426	1174	3566
Interest	21	5	24	29	33	35	53	41	73	98	56
Depreciation	168	337	306	366	390	426	519	503	514	548	725
Exceptional Income / Expenses	0	0	0	0	0	-340	-759	0	0	0	0
Profit Before Tax	3139	3212	3844	4179	1794	2342	1052	1630	-162	527	2785
Provision for Tax	815	815	1013	1038	449	804	325	371	27	102	459
Profit After Tax	2324	2397	2831	3141	1345	1539	728	1259	-189	425	2326
Adjustments	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	2324	2397	2831	3141	1345	1539	728	1259	-189	425	2326
Adjusted Earnings Per Share	51.8	53.3	62.8	69.6	29.7	34	16.1	27.7	-4.2	9.3	51

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	30%	10%	5%	5%
Operating Profit CAGR	204%	18%	3%	1%
PAT CAGR	447%	23%	9%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	98%	32%	24%	5%
ROE Average	12%	4%	5%	15%
ROCE Average	14%	6%	7%	20%

Lupin Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	6979	9028	11913	14780	15785	17117	17473	18566	18150	18412	20603
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	24	19	14	9	4	1	0	0	0	0	0
Other Non-Current Liabilities	334	301	354	494	556	575	651	707	625	644	626
Total Current Liabilities	1461	1660	1955	2566	2336	1997	2556	2586	3538	3628	3646
Total Liabilities	8799	11008	14236	17848	18681	19690	20681	21859	22313	22684	24923
Fixed Assets	2179	2036	2345	3013	3341	3373	3514	3639	3690	4022	4113
Other Non-Current Assets	1576	2520	4635	5585	6623	6833	6328	8602	10185	11091	11522
Total Current Assets	5044	6452	7256	9251	8709	9485	10839	9617	8438	7571	9140
Total Assets	8799	11008	14236	17848	18681	19690	20681	21859	22313	22684	24923

Lupin Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	18	255	1714	18	158	106	56	1168	177	59	86
Cash Flow from Operating Activities	1528	2852	917	4352	209	3111	2219	1570	151	1794	2504
Cash Flow from Investing Activities	-447	-1178	-2629	-1941	725	-2865	-740	-2508	-372	-1269	-1599
Cash Flow from Financing Activities	-844	-221	17	-160	-987	-295	-368	-53	102	-498	-867
Net Cash Inflow / Outflow	237	1452	-1696	2252	-52	-50	1112	-991	-118	27	38
Closing Cash & Cash Equivalent	255	1708	18	2270	106	56	1168	177	59	86	124

Lupin Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	51.83	53.33	62.82	69.56	29.74	34.01	16.06	27.74	-4.15	9.35	51.04
CEPS(Rs)	55.57	60.83	69.61	77.67	38.36	43.43	27.51	38.82	7.16	21.4	66.95
DPS(Rs)	6	7.5	7.5	7.5	5	5	6	6.5	4	4	8
Book NAV/Share(Rs)	155.06	199.59	261.84	323.44	344.47	373.46	380.98	405.03	395.79	401.4	449.64
Core EBITDA Margin(%)	32.29	34.26	35.15	34.88	19.29	23.57	16.12	17.18	1.56	8.52	23.34
EBIT Margin(%)	35.03	32.67	34.1	32.72	16.9	19.64	9.34	14.04	-0.67	5.53	19.28
Pre Tax Margin(%)	34.8	32.62	33.89	32.49	16.59	19.35	8.89	13.7	-1.23	4.66	18.9
PAT Margin (%)	25.77	24.35	24.96	24.42	12.44	12.71	6.15	10.58	-1.43	3.76	15.79
Cash Profit Margin (%)	27.63	27.77	27.65	27.27	16.04	16.23	10.53	14.81	2.47	8.6	20.71
ROA(%)	29.34	24.21	22.43	19.58	7.36	8.02	3.6	5.92	-0.85	1.89	9.77
ROE(%)	39.42	30.11	27.26	23.79	8.91	9.48	4.26	7.06	-1.04	2.35	12
ROCE(%)	50.01	39.73	36.19	30.41	11.72	14.44	6.39	9.19	-0.47	3.3	14.33
Receivable days	95.79	99.63	113.59	119.87	149.36	130.71	113.21	104.42	81.97	87.01	80.72
Inventory Days	54.69	57.68	58.78	57.32	72.67	67.63	73.88	79.66	81.59	99.91	74.18
Payable days	114.96	119.49	121.94	140.88	153.05	125	125.75	127.82	115.55	124.2	156.12
PER(x)	18.06	37.63	23.56	20.77	24.76	21.73	36.72	36.8	0	69.32	31.7
Price/Book(x)	6.04	10.06	5.65	4.47	2.14	1.98	1.55	2.52	1.88	1.61	3.6
Dividend Yield(%)	0.64	0.37	0.51	0.52	0.68	0.68	1.02	0.64	0.54	0.62	0.49
EV/Net Sales(x)	4.69	9.25	5.97	5.15	3.29	2.94	2.3	4.19	2.94	2.66	5.02
EV/Core EBITDA(x)	12.61	25.38	16.07	14.35	14.97	10.62	10.67	21.32	81.28	25.55	20.64
Net Sales Growth(%)	25.51	9.1	15.12	13.59	-20.9	12.57	-2.91	0.27	6.47	-4.36	30.27
EBIT Growth(%)	79.85	1.8	20.24	8.8	-56.58	30.14	-53.54	51.18	-105.27	810.4	354.15
PAT Growth(%)	84.4	3.15	18.08	10.97	-57.19	14.44	-52.72	72.99	-114.99	325.34	447.05
EPS Growth(%)	84.05	2.89	17.8	10.72	-57.24	14.34	-52.77	72.73	-114.97	325.09	446.2
Debt/Equity(x)	0.02	0.01	0.03	0.04	0	0	0	0.02	0.04	0.03	0
Current Ratio(x)	3.45	3.89	3.71	3.61	3.73	4.75	4.24	3.72	2.38	2.09	2.51
Quick Ratio(x)	2.51	2.84	2.73	2.78	2.79	3.59	3.27	2.67	1.49	1.25	1.69
Interest Cover(x)	150.55	656.55	160.44	143.05	54.97	67.04	21.01	41.12	-1.2	6.35	50.42
Total Debt/Mcap(x)	0	0	0.01	0.01	0	0	0	0.01	0.02	0.02	0

Lupin Shareholding Pattern

#	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoter	46.78	47.1	47.11	47.1	47.08	47.07	47.06	47.04	47.01	46.98
FII	14.65	14.27	13.81	13.98	13.32	13.94	14.99	16.11	18.28	19.32
DII	27.19	27.19	27.63	29.39	29.2	29.36	29.43	29.73	27.77	26.78
Public	11.37	11.45	11.45	9.53	10.4	9.64	8.52	7.11	6.93	6.92
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoter	21.26	21.41	21.42	21.42	21.42	21.42	21.42	21.42	21.42	21.42
FII	6.66	6.49	6.28	6.36	6.06	6.34	6.83	7.34	8.33	8.81
DII	12.36	12.36	12.56	13.36	13.29	13.36	13.4	13.54	12.66	12.21
Public	5.17	5.2	5.21	4.33	4.73	4.39	3.88	3.24	3.16	3.15
Others	0	0	0	0	0	0	0	0	0	0
Total	45.45	45.46	45.47	45.48	45.5	45.51	45.52	45.53	45.57	45.59

Pros

Company is almost debt free.

Cons

Promoter holding is low: 46.98%.
Company has a low return on equity of 4% over the last 3 years.
Debtor days have increased from 124.2 to 156.12days.
Stock is trading at 4.8 times its book value.
The company has delivered a poor profit growth of 8% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Lupin News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Lupin

Add Watchlist

Lupin Research see more...

Overview Inc. Year: 1983Industry: Pharmaceuticals & Drugs

Lupin Share Price

Alert Data

Quarterly Price

Peer Comparison

Lupin Quarterly Results

Lupin Profit & Loss

Growth Rates

Lupin Balance Sheet

Lupin Cash Flow

Lupin Ratios

Lupin Shareholding Pattern

Lupin News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!